You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
The UPS: a promising target for breast cancer treatment
|
|---|---|
| Published in |
BMC Molecular and Cell Biology, October 2008
|
| DOI | 10.1186/1471-2091-9-s1-s2 |
| Pubmed ID | |
| Authors |
Ko Sato, Eeson Rajendra, Tomohiko Ohta |
| Abstract |
During the past decade, progress in endocrine therapy and the use of trastuzumab has significantly contributed to the decline in breast cancer mortality for hormone receptor-positive and ERBB2 (HER2)-positive cases, respectively. As a result of these advances, a breast cancer cluster with poor prognosis that is negative for the estrogen receptor (ESR1), the progesterone receptor (PRGR) and ERBB2 (triple negative) has come to the forefront of medical therapeutic attention. DNA microarray analyses have revealed that this cluster is phenotypically most like the basal-like breast cancer that is caused by deficiencies in the BRCA1 pathways. To gain further improvements in breast cancer survival, new types of drugs might be required, and small molecules targeting the ubiquitin proteasome system have moved into the spotlight. The success of bortezomib in the treatment of multiple myeloma has sent encouraging signals that proteasome inhibitors could be used to treat other types of cancers. In addition, ubiquitin E3s involved in ESR1, ERBB2 or BRCA1 pathways could be ideal targets for therapeutic intervention. This review summarizes the ubiquitin proteasome pathways related to these proteins and discusses the possibility of new drugs for the treatment of breast cancers. PUBLICATION HISTORY : Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com). |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Chile | 1 | 2% |
| Ireland | 1 | 2% |
| Italy | 1 | 2% |
| Spain | 1 | 2% |
| Japan | 1 | 2% |
| Unknown | 58 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 23% |
| Student > Ph. D. Student | 11 | 17% |
| Other | 7 | 11% |
| Student > Master | 6 | 9% |
| Professor | 3 | 5% |
| Other | 14 | 22% |
| Unknown | 8 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 23 | 36% |
| Medicine and Dentistry | 14 | 22% |
| Biochemistry, Genetics and Molecular Biology | 8 | 13% |
| Economics, Econometrics and Finance | 2 | 3% |
| Computer Science | 1 | 2% |
| Other | 6 | 9% |
| Unknown | 10 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 January 2015.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from BMC Molecular and Cell Biology
#1,054
of 1,233 outputs
Outputs of similar age
#98,967
of 102,854 outputs
Outputs of similar age from BMC Molecular and Cell Biology
#28
of 28 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,233 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 102,854 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.